Bluebird Bio gene therapy sells itself to Carlyle and SK Capital
Sopa Images | Lightrocket | Getty Images Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday, marking the end of the Bluebird’s fall from the one of the buzziest biotech firms to one that was on the cusp of running out of money. … Read more